Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 May;26(2):19-39.

Insulin and insulin resistance

Gisela Wilcox  1
Affiliations

Insulin and insulin resistance

Gisela Wilcox. Clin Biochem Rev. 2005 May.

Abstract

As obesity and diabetes reach epidemic proportions in the developed world, the role of insulin resistance and its consequences are gaining prominence. Understanding the role of insulin in wide-ranging physiological processes and the influences on its synthesis and secretion, alongside its actions from the molecular to the whole body level, has significant implications for much chronic disease seen in Westernised populations today. This review provides an overview of insulin, its history, structure, synthesis, secretion, actions and interactions followed by a discussion of insulin resistance and its associated clinical manifestations. Specific areas of focus include the actions of insulin and manifestations of insulin resistance in specific organs and tissues, physiological, environmental and pharmacological influences on insulin action and insulin resistance as well as clinical syndromes associated with insulin resistance. Clinical and functional measures of insulin resistance are also covered. Despite our incomplete understanding of the complex biological mechanisms of insulin action and insulin resistance, we need to consider the dramatic social changes of the past century with respect to physical activity, diet, work, socialisation and sleep patterns. Rapid globalization, urbanisation and industrialization have spawned epidemics of obesity, diabetes and their attendant co-morbidities, as physical inactivity and dietary imbalance unmask latent predisposing genetic traits.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic presentation of insulin secretory pathways. Adapted from references: & . Footnotes: Figure Abbreviations Akt/PKB = protein kinase B GLP-1 = glucagon-like peptide 1 ATP = adenosine triphosphate IRS = insulin receptor substrate ADP = adenosine diphosphate MAP kinase = mitogen activated protein kinase cAMP= cyclic adenosine monophosphate PACAP = pituitary adenylate cyclase-activating polypeptide DAG = diacylglycerol PI3K = phosphatidylinositol 3-kinase GIP = gastric inhibitory peptide / PIPD1 & 2 = phosphatidylinositol dependent protein kinases 1 & 2 glucose-dependent insulinotropic polypeptide PKC = protein kinase C Glucose- 6- P = glucose 6 phosphate RAS = rat sarcoma protein GLUT 2 = glucose transport protein 2 SHC =adaptor protein with src-homology GLUT 4 = glucose transport protein 4 VIP= vasoactive intestinal peptide
Figure 2
Figure 2
Schematic presentation of insulin signalling pathways. Adapted from references: , & . Footnotes: Figure Abbreviations Akt/PKB = protein kinase B GLP-1 = glucagon-like peptide 1 ATP = adenosine triphosphate IRS = insulin receptor substrate ADP = adenosine diphosphate MAP kinase = mitogen activated protein kinase cAMP= cyclic adenosine monophosphate PACAP = pituitary adenylate cyclase-activating polypeptide DAG = diacylglycerol PI3K = phosphatidylinositol 3-kinase GIP = gastric inhibitory peptide / PIPD1 & 2 = phosphatidylinositol dependent protein kinases 1 & 2 glucose-dependent insulinotropic polypeptide PKC = protein kinase C Glucose- 6- P = glucose 6 phosphate RAS = rat sarcoma protein GLUT 2 = glucose transport protein 2 SHC =adaptor protein with src-homology GLUT 4 = glucose transport protein 4 VIP= vasoactive intestinal peptide
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic Report of a WHO Consultation Technical Report Series. World Health Organization, Geneva 2000. - PubMed
    1. Cefalu WT. Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 2001;226:13–26. - PubMed
    1. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33:283–303. - PubMed
    1. Bliss M. The history of insulin Diabetes Care. 1993;16(Suppl 3):4–7. - PubMed
    1. Home PD. Insulin therapy. In: Alberti KGMM, Zimmet P, Defronzo RA editors & Keen H (Hon) editor International Textbook of Diabetes Mellitus (2nd ed) John Wiley & Sons, New York; 1997 p. 899–928.

LinkOut - more resources